Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, United States of America.
Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, United States of America.
Epilepsy Behav. 2020 Oct;111:107284. doi: 10.1016/j.yebeh.2020.107284. Epub 2020 Jul 8.
Lamotrigine (LTG) is one of the most used antiseizure medications (ASMs). Titration is indicated for incomplete seizure control, but toxicity with vertigo, ataxia, and diplopia may ensue. Lamotrigine concentration would be the optimal diagnostic test. However, patients often receive a stroke evaluation when presenting to the emergency department (ED), leading to unnecessary cost and delayed management. We investigated the frequency of stroke evaluation for symptoms associated with LTG toxicity and attempted to identify factors leading to this expensive evaluation.
We identified adult patients treated with LTG who presented to an emergency room with dizziness, ataxia, or diplopia and received a negative stroke evaluation, between 2003 and 2018. They were among 972 patients treated with LTG for epilepsy. We collected age at time of occurrence, symptoms presented, imaging studies performed, LTG dose and serum concentration, and the time the result was available. As a denominator, we also identified patients who developed clinical LTG toxicity during the same time period.
Thirteen patients with LTG toxicity had 16 negative stroke evaluations in the emergency room. Their mean age was 62 years (range: 43-79) as compared with 47 years for all patients treated with LTG (p < 0.0005). The mean daily LTG dose was 621 mg (range: 300-900 mg). A LTG serum concentration was requested on the day of evaluation in 7 instances, though the result was never available until at least the next day. In 4 instances, the LTG level was drawn 1-3 days after presentation. Five of the patients in this group were among 71 patients with clinical LTG toxicity and LTG concentration >20.
Emergency departments will frequently call a stroke alert for patients taking LTG and presenting with symptoms consistent with LTG toxicity, particularly in seniors at greater risk of stroke. This adds not only expense but also radiation and contrast exposure from computed tomography (CT) studies. We recommend that a rapid LTG assay be made available and always ordered in patients receiving LTG, avoiding the considerable expense of an unnecessary stroke evaluation.
拉莫三嗪(LTG)是最常用的抗癫痫药物(ASMs)之一。对于控制不完全的癫痫发作,需要进行滴定,但是可能会出现眩晕、共济失调和复视等毒性反应。LTG 浓度将是最佳的诊断测试。然而,当患者到急诊室(ED)就诊时,通常会接受中风评估,导致不必要的费用和延迟管理。我们调查了因 LTG 毒性相关症状而进行中风评估的频率,并试图确定导致这种昂贵评估的因素。
我们确定了 2003 年至 2018 年间在急诊室因头晕、共济失调或复视而接受阴性中风评估且正在接受 LTG 治疗的癫痫患者。他们是 972 名接受 LTG 治疗的癫痫患者之一。我们收集了发病时的年龄、出现的症状、进行的影像学检查、LTG 剂量和血清浓度以及结果可用的时间。作为分母,我们还确定了在同一时期出现临床 LTG 毒性的患者。
13 名 LTG 毒性患者在急诊室进行了 16 次阴性中风评估。他们的平均年龄为 62 岁(范围:43-79 岁),而所有接受 LTG 治疗的患者平均年龄为 47 岁(p<0.0005)。LTG 的平均日剂量为 621mg(范围:300-900mg)。7 例在评估当天要求进行 LTG 血清浓度检测,但结果至少要到第二天才能获得。在 4 例中,LTG 水平是在就诊后 1-3 天抽取的。在 7 名出现临床 LTG 毒性和 LTG 浓度>20 的患者中,有 5 名属于该组。
急诊科会经常为服用 LTG 并出现与 LTG 毒性一致的症状的患者发出中风警报,特别是在中风风险较高的老年人中。这不仅增加了费用,还增加了来自计算机断层扫描(CT)研究的辐射和对比暴露。我们建议为正在接受 LTG 治疗的患者提供快速的 LTG 检测,并始终进行检测,避免不必要的中风评估带来的巨大费用。